Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263129 | 0.89 | MTNR1A (0.53) | SSTR4POLBMTNR1AMTNR1BNPC1 | |
| SCHEMBL14263082 | 0.81 | EPHX1 (0.71) | NPC1RAB9ASMN1; SMN2EPHX2ALDH1A1 | |
| SCHEMBL4975779 | 0.78 | DRD4 (0.59) | SSTR4NPC1RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL14263114 | 0.78 | DRD4 (0.73) | POLBRAB9ASMN1; SMN2EPHX2HPGD | |
| SCHEMBL5471733 | 0.76 | NPC1 (0.61) | POLBMTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL13305516 | 0.76 | LTA4H (0.55) | SSTR4NPC1SMN1; SMN2LTA4HSLC6A5 | |
| SCHEMBL4981401 | 0.76 | SMN1; SMN2 (0.54) | SSTR4NPC1RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL21749041 | 0.75 | SSTR4 (1.00) | SSTR4 | |
| SCHEMBL4981131 | 0.75 | SSTR4 (0.59) | SSTR4PKMEPHX2ALDH1A1 | |
| SCHEMBL13305529 | 0.75 | KDM4E (0.56) | NPC1SMN1; SMN2LTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | SSTR4 654/4885POLB 3173/4885MTNR1A 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.